Memoirs of a Reincarnated T Cell  by Crompton, Joseph G. et al.
Cell Stem Cell
In TranslationMemoirs of a Reincarnated T CellJoseph G. Crompton,1 Mahendra Rao,2 and Nicholas P. Restifo1,2,*
1National Cancer Institute
2Center for Regenerative Medicine
National Institutes of Health, Bethesda, MD 20892, USA
*Correspondence: restifon@mail.nih.gov
http://dx.doi.org/10.1016/j.stem.2012.12.009
In two studies published in this issue ofCell StemCell,Nishimura et al. (2013) and Vizcardo et al. (2013) repro-
gram mature, antigen-specific cytotoxic T cells into induced pluripotent stem cells (iPSCs). The antigen-
specific iPSCs can be redifferentiated into ‘‘rejuvenated’’ proliferative T cells and have broad applications
for adoptive immunotherapy.One method to confirm the identity of the
reincarnated Dalai Lama involves placing
several artifacts, only a few of which
belonged to the previous Dalai Lama, in
front of a candidate child. If the child
recognizes an artifact which belonged to
the previous Dalai Lama, this is inter-
preted as a sign that the child is indeed
the reincarnated Lama. In the recent
work by Nishimura (Nishimura et al.,
2013) and Vizcardo (Vizcardo et al.,
2013) presented in this issue of Cell
Stem Cell, we are also witnesses to a
majestic reincarnation of sorts. Both
groups reprogrammed human antigen-
specific CD8+ mature T cells into induced
pluripotent stem cells (iPSCs). Further-
more, they showed that redifferentiation
of these cells produced CD8+ T cells
that recognize their original cognate
antigen and have features of rejuvenated
cells so critically needed to improve the
efficacy of T-cell-based therapies for the
treatment of cancer and viral-associated
diseases (Fearon, 2007).
Needless to say, the regeneration of
antigen-specific T cells from iPSCs
derived from mature CD8+ T cells pro-
vides yet another example of the reach
of Yamanaka’s discovery that induction
of four transcription factors—Oct4,
Sox2, Klf4, and c-Myc—can reprogram
well-differentiated somatic cells to plurip-
otency (Takahashi and Yamanaka, 2006).
The field of regenerative medicine and
the stem cell community continue to
profit from Yamanaka’s finding that was
fittingly celebrated in Stockholm last
month. Amidst immense enthusiasm
over the therapeutic potential of iPSCs,
however, remain obstacles in translating
this discovery to improve the care of
patients (Wu and Hochedlinger, 2011).6 Cell Stem Cell 12, January 3, 2013 ª2013 EBy focusing on the reprogramming of
the immune system in adoptive cell trans-
fer immunotherapy, the work of Nishi-
mura et al. and Vizcardo et al. may
provide an opportunity to hasten the
bench-to-bedside translation of iPSC
technology.
Adoptive cell transfer immunotherapy
(ACT) of T cells shows great promise in
treating patients with advanced cancer,
graft-versus-host disease, and viral-asso-
ciated diseases. As a therapy to treat
cancer, for example, ACT relies on the
natural ability of CD8+ T cells (called
tumor-infiltrating lymphocytes, or TILs)
to attack tumors (Restifo et al., 2012).
The dogged persistence of cancer,
however, often results in CD8+ T cells
that are both exhausted and senescent
(Klebanoff et al., 2006). With ACT, the
tumor-specific TILs are harvested from
a patient’s tumor, expanded ex vivo with
the immunostimulatory cytokine IL-2,
and infused back into the same patient
(Figure 1). Remarkably, up to 20% of
patients with advanced melanoma have
had complete and durable regression of
their metastatic disease (Rosenberg,
2011). In trying to understand why this
cohort of patients had such an extra-
ordinary response, it was found that
transfer of less-differentiated memory or
stem-cell-like CD8+ T cells correlated
with a more robust eradication of tumor.
Therefore, there is a critical need to
improve the efficacy of ACT by devel-
oping methods such as iPSC technology
to expand the pool of memory or stem-
cell-like CD8+ T cells (Gattinoni et al.,
2011).
In their study, Vizcardo et al. attempt to
address this need by obtaining TILs from
one of our patients suffering from meta-lsevier Inc.static melanoma at the Surgery Branch
of the National Cancer Institute. The TILs
have an antigen specificity for MART-1,
which is commonly expressed on mela-
noma tumors. The MART-1-specific TILs
were transduced with Yamanaka factors
and reprogrammed to iPSCs as evi-
dencedbyESC-likemorphology, capacity
for teratoma formation, endogenous
expression of OCT3/4, SOX2, KLF4, and
c-MYC, and disappearance of T cell
markers CD3 and CD8. Subsequent
coculture with Delta-like 1 expressing
OP9 feeder cells resulted in redifferen-
tation to CD8+ T cells (Schmitt and Zu´-
n˜iga-Pflu¨cker, 2002). When cultured
with antigen presenting cells and chal-
lenged with the cognate antigen MART-
1, reprogrammed cells produced inter-
feron gamma, demonstrating functional
integrity.
Although Vizcardo and colleagues
show that reincarnated CD8+ T cells
have a memory for their original tumor
antigen, it is not clear if reincarnated cells
are indeed rejuvenated. That is, does the
reprogramming process confer greater
replicative capacity, multipotency, and
antitumor immunity that is characteristic
of memory or stem-cell-like T cells? We
know that TILs are generally character-
ized by a state of exhaustion and terminal
differentiation. Thus, the lingering ques-
tion is whether the reincarnated cells
have preserved a memory or stem-cell-
like phenotype so critical to improving
the efficacy of ACT for cancer or viral
infection.
Nishimura et al. provide additional
insight into whether terminally differenti-
ated CD8+ T cells can be rejuvenated
through reprogramming by showing that
redifferentiated CD8+ T cells have
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Figure 1. Reprogramming an Exhausted Immune System for Treatment of Cancer
(A) Generalized model of T cell differentiation. An immune response is initiated when naive CD8+ T cells (TN) are activated by their cognate antigen to undergo
clonal expansion and differentiation into subsets characterized here by a reciprocally graded capacity for self-renewal and cytolytic effector function. Although
eradication of tumor ultimately requires robust cytolytic function of terminally differentiated effector (TEFF) cells, therapeutic efficacy of ACT is improved by trans-
fer of less-differentiated cells because of their ability for self renewal and survival and their ability to generate TEFF progeny.
(B) Rejuvenating T cells with Yamanaka factors. Adoptive T-cell-based immunotherapy (ACT) for cancer involves isolating CD8+ lymphocytes from a surgically
excised tumor and expanding the cells ex vivo with T cell growth factor IL-2. Lymphocytes are subsequently infused back into the patient to attack the remaining
tumor sites. Lymphocytes isolated from the tumor generally have a terminally differentiated effector (TEFF) or effectormemory (TEM) phenotype, and the IL-2 driven
expansion results in further differentiation. There is considerable evidence that transfer of less-differentiated lymphocytes such as stem-cell memory T cells
(TSCM) or central memory T cells (TCM) results in substantially greater antitumor immunity. Therefore, rejuvenating lymphocytes to a less-differentiated state using
induced pluripotent stem cell (iPSC) technology shows great promise in substantially improving the efficacy of ACT. Reprogramming with Yamanaka factors and
redifferentiation with Delta-like 1 expressing OP9 (OP9/DLL1) stromal cells rejuvenates lymphocytes and preserves less-differentiated TSCM and TCM CD8
+ T cell
subsets that may result in improved eradication of tumor when transferred into cancer patients.
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ative capacity. Using an HIV-1-epitope
specific clone of CD8+ T cells, they
demonstrate reprogramming through an
iPSC intermediate into functional CD8+
T cells capable of cytolytic activity and
interferon gamma release with recogni-
tion of their cognate peptide. Importantly,
the cells also show enhanced expression
of CCR7, CD27, and CD28, revealing
characteristic stem-cell-like traits com-
pared to the original T cell clone from
which the cells were derived (Gattinoni
et al., 2011). In fact, reincarnated CD8+
T cells have even longer telomeres than
their original counterparts, perhaps im-
parted by their sojourn through the iPSC
state where telomerase activity runs hot.
The authors duly recognize that the clin-
ical translation of rejuvenating cytotoxic
T cells to treat patients with HIV is compli-cated, and with good reason, but we
feel this remains a remarkable demon-
stration of rejuvenated T cells and is an
important first step in broadening the
therapeutic application of ACT to treat
maladies whose common denominator
is a terminally differentiated and ex-
hausted immune response.
Taken together, the work of the two
groups led by Vizcardo and Nishimura
demonstrate that antigen-experienced
CD8+ T cells can be reincarnated through
an iPSC intermediate into CD8+ T cells
that preserve memory for their original
epitope, and moreover, develop a rejuve-
nated memory phenotype upon rediffer-
entiation. This has important clinical
implications for ACT because it pro-
vides proof of concept that terminally
differentiated lymphocytes can be reincar-
nated from an exhausted state toCell Stem Cela memory phenotype that may have
demonstrablysuperior antitumor immunity
(Figure 1). We look forward to further
preclinical work investigating the efficacy
of reprogrammed T cells in eradicating
tumors and chronic viral diseases and
feel thismaybeaparticularly fruitfulmeans
to hasten the bench-to-bedside transla-
tion of iPSC technology and regenerative
medicine for the treatment of patients
with viral-associateddiseasesandcancer.REFERENCES
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Thrombopoietin (TPO) attracts much attention as an effective stimulus for blood cell formation in patients
with hematopoietic disorders. In this issue of Cell Stem Cell, de Laval et al. (2013) show that TPO can also
promote ‘‘healthy’’ hematopoietic stem cells when administered before radiotherapy to minimize HSC injury
and mutagenesis in mice.Thrombopoietin (TPO) has a well-de-
scribed role as a principal regulator of
platelet production, which is stimulated
through binding to its receptor Mpl on
megakaryocytes. More recently, studies
have revealed important roles for TPO/
Mpl signaling in hematopoietic stem cells
(HSCs) as well (reviewed in Chou and
Mulloy, 2011). Mpl is expressed in HSCs
and progenitors, and TPO cooperates
with other cytokines to promote expan-
sion of HSCs in culture. Mice deficient
in TPO and Mpl signaling have reduced
numbers of HSCs with impaired repopu-
lating ability as well as the defective
platelet formation one would expect.
Clinically, inactivating mutations of Mpl
in humans cause thrombocytopenia and
multilineage marrow failure, while acti-
vating Mpl mutations are involved in
myeloproliferative disorders. These ob-
servations demonstrate an important
role of TPO/Mpl signaling in HSCs and
progenitors. As a mechanism for TPO-
mediated HSC regulation, it was shown
that TPO regulates HSC quiescence and
interaction with the osteoblastic niche
(Qian et al., 2007; Yoshihara et al., 2007).
Cells in the human body are continually
exposed to DNA stresses. Physiological
stresses as well as environmental
agents, such as ionizing radiation (IR)
and other genotoxic chemicals, induceDNA damage including double-strand
breaks (DSBs). DNA repair is essential
for cell survival, and the long lifespan of
HSCs suggests that they need an effec-
tive DNA repair process to maintain a
‘‘healthy’’ state. DNA damage is repaired
through two main pathways: homologous
recombination (HR) and nonhomolo-
gous end joining (NHEJ). Recent data
showed that quiescent HSCs preferen-
tially use NHEJ repair mechanism, and
DSB repair through NHEJ is necessary
for HSC maintenance (Mohrin et al.,
2010; Nijnik et al., 2007; Rossi et al.,
2007).
In this issue of Cell Stem Cell, de Laval
et al. (2013) discovered a new function
of TPO in DNA damage response in
HSCs and progenitors. They found that
Mpl-deficient HSCs and progenitors
had significantly increased numbers of
gH2AX foci (a marker of DSB formation)
after exposure to IR or topoisomerase-II
inhibitors relative to wild-type cells. A
neutral comet assay (another technique
for the detection of DSBs) also showed
IR-induced DNA damage was greatly
enhanced in Mpl-deficient cells. Consis-
tent with these findings, HSCs treated in
the absence of TPO showed similar DSB
repair defects and, conversely, TPO injec-
tion into mice just before IR reduced the
number of gH2AX in HSCs in vivo. Nodifferences in cell cycle and apoptotic
status of HSCs were apparent under
these experimental settings, implying the
TPO/Mpl signaling was affecting DNA
damage in HSCs through a direct effect
on the DNA repair process. Other hema-
topoietic cytokines such as SCF and
FLT3 ligand did not show such effects,
suggesting that the DNA repair activity is
a specific function of TPO. de Laval et al.
(2013) found that TPO increased phos-
phorylation of the DNA-PK catalytic
subunit (a central player in NHEJ), and
pharmacological or genetic inhibition of
DNA-PK abolished TPO-mediated DNA
repair. TPO did not increase IR-induced
Rad51 foci formation nor did it improve
repair of DSBs induced by replicative
stress, indicating HR was not involved in
this DSB repair. Taken together, these
results indicate that TPO/Mpl promotes
NHEJ-mediated DNA repair by stimu-
lating DNA-PK activity in HSCs. Impor-
tantly, TPO treatment before IR limits
IR-induced HSC injury and increases
HSC function for long-term hematopoietic
reconstitution, raising the potential
clinical application of TPO agonists in
patients receiving radiotherapy or chemo-
therapy. The findings also imply that
agonists of TPO/mpl may be effective in
patients suffering from inefficient hemato-
poiesis caused by damaged HSCs.
